springworks
therapeutics
enters
sponsored
research
agreement
fred
hutchinson
cancer
research
center
evaluate
nirogacestat
bcma
potentiator
multiple
myeloma
stamford
globe
newswire
springworks
therapeutics
nasdaq
swtx
biopharmaceutical
company
focused
developing
medicines
patients
severe
rare
diseases
cancer
today
announced
entered
sponsored
research
agreement
fred
hutchinson
cancer
research
center
fred
hutch
explore
ability
springworks
investigational
gamma
secretase
inhibitor
gsi
nirogacestat
modulate
maturation
antigen
bcma
potentiate
therapies
including
radioimmunotherapies
variety
preclinical
multiple
myeloma
models
developed
researchers
fred
hutch
damian
green
associate
member
clinical
research
division
fred
hutch
associate
professor
university
washington
school
medicine
serve
principal
investigator
research
gamma
secretase
inhibition
disrupts
cleavage
shedding
bcma
surface
myeloma
cells
preclinical
models
team
fred
hutch
first
show
gamma
secretase
inhibition
increase
bcma
surface
density
malignant
plasma
cells
concurrently
decrease
soluble
bcma
enhance
activity
nirogacestat
demonstrated
similar
addition
emerging
published
clinical
data
fred
hutch
suggest
gsi
may
increase
antitumor
efficacy
autologous
car
cell
therapy
patients
relapsed
refractory
multiple
already
begun
see
multiple
myeloma
patients
appear
benefit
ability
gsi
potentiate
therapies
said
green
given
clinical
experience
nirogacestat
commitment
springworks
made
combining
gsi
therapies
look
forward
expanding
important
work
fred
hutch
already
done
area
collaborating
springworks
explore
therapeutic
hypothesis
fred
hutch
scientists
leaders
developing
novel
treatment
approaches
multiple
myeloma
presented
promising
preclinical
clinical
data
combining
gsis
therapies
said
saqib
islam
chief
executive
officer
springworks
therapeutics
believe
nirogacestat
potential
become
cornerstone
bcma
combination
therapies
across
modalities
delighted
working
green
build
upon
encouraging
results
demonstrated
date
ultimate
goal
develop
nirogacestat
way
improve
clinical
outcomes
patients
multiple
nirogacestat
nirogacestat
investigational
oral
selective
small
molecule
gamma
secretase
inhibitor
phase
clinical
development
desmoid
tumors
rare
often
debilitating
disfiguring
tumors
gamma
secretase
cleaves
multiple
transmembrane
protein
complexes
including
notch
believed
play
role
activating
pathways
contribute
desmoid
tumor
growth
addition
gamma
secretase
shown
directly
cleave
bcma
resulting
release
bcma
extracellular
domain
ecd
cell
surface
inhibiting
gamma
secretase
bcma
preserved
increasing
target
density
reducing
levels
soluble
bcma
ecd
may
serve
decoy
receptors
therapies
nirogacestat
ability
enhance
activity
therapies
observed
preclinical
models
multiple
myeloma
springworks
evaluating
nirogacestat
bcma
potentiator
three
collaborations
bcma
developers
evaluate
nirogacestat
combinations
across
modalities
including
conjugate
car
cell
therapy
bispecific
antibody
addition
springworks
fred
hutchinson
cancer
research
center
entered
sponsored
research
agreement
characterize
ability
nirogacestat
modulate
bcma
potentiate
bcma
directed
therapies
using
variety
preclinical
multiple
myeloma
models
developed
researchers
fred
hutch
nirogacestat
received
orphan
drug
designation
food
drug
administration
fda
treatment
desmoid
tumors
june
european
commission
treatment
soft
tissue
sarcoma
september
fda
also
granted
fast
track
breakthrough
therapy
designations
treatment
adult
patients
progressive
unresectable
recurrent
refractory
desmoid
tumors
deep
fibromatosis
november
august
springworks
therapeutics
springworks
biopharmaceutical
company
applying
precision
medicine
approach
acquiring
developing
commercializing
medicines
underserved
patient
populations
suffering
devastating
rare
diseases
cancer
springworks
differentiated
portfolio
small
molecule
targeted
oncology
product
candidates
advancing
two
potentially
registrational
clinical
trials
rare
tumor
types
well
several
programs
addressing
highly
prevalent
genetically
defined
cancers
springworks
strategic
approach
operational
excellence
clinical
development
enabled
rapidly
advance
two
lead
product
candidates
clinical
trials
simultaneously
entering
multiple
partnerships
industry
leaders
expand
portfolio
information
visit
follow
springworkstx
twitter
linkedin
springworks
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
including
without
limitation
statements
regarding
springworks
clinical
trials
strategy
business
plans
focus
words
may
could
would
expect
plan
anticipate
intend
believe
estimate
predict
project
potential
continue
target
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
press
release
based
management
current
expectations
beliefs
subject
number
risks
uncertainties
important
factors
may
cause
actual
events
results
differ
materially
expressed
implied
statements
contained
press
release
including
without
limitation
related
springworks
financial
results
timing
completion
springworks
clinical
trials
product
candidates
whether
springworks
product
candidates
receive
approval
food
drug
administration
fda
foreign
regulatory
authorities
uncertainties
assumptions
regarding
impact
pandemic
springworks
business
operations
clinical
trials
supply
chain
strategy
goals
anticipated
timelines
competition
biopharmaceutical
companies
risks
identified
section
entitled
risk
factors
item
part
ii
springworks
quarterly
report
form
quarter
ended
june
well
discussions
potential
risks
uncertainties
important
factors
springworks
subsequent
filings
securities
exchange
commission
springworks
cautions
place
undue
reliance
statements
speak
date
made
springworks
disclaims
obligation
publicly
update
revise
statements
reflect
change
expectations
events
conditions
circumstances
statements
may
based
may
affect
likelihood
actual
results
differ
set
forth
statements
statements
contained
press
release
represent
springworks
views
date
hereof
relied
upon
representing
views
subsequent
date
springworks
media
investor
contact
kim
diamond
kdiamond
references
pont
mj
hill
cole
go
et
al
inhibition
increases
efficacy
chimeric
antigen
receptor
cells
multiple
myeloma
blood
hill
pont
mj
abbott
j
et
al
gamma
secretase
inhibition
increases
recognition
multiple
myeloma
chimeric
antigen
receptor
modified
cells
presented
annual
meeting
society
immunotherapy
cancer
sitc
november
national
harbor
md
eastman
shelton
c
gupta
krueger
j
blackwell
c
bojczuk
synergistic
activity
belantamab
mafodotin
inhibitor
cancer
cell
lines
blood
cowen
aj
pont
sather
bd
et
al
efficacy
safety
fully
human
bcma
car
cells
combination
gamma
secretase
inhibitor
increase
bcma
surface
expression
patients
relapsed
refractory
multiple
myeloma
blood
